Two Onc Docs

The podcast discusses the presentation, diagnosis, and treatment of Mantle Cell Lymphoma. They cover the workup, diagnostic criteria, and treatment options for both limited stage and advanced cases. They also explore various treatment options based on patient age and fitness, including stem cell transplant and agents for relapsed or refractory cases.

This podcast explores Adrenocortical Carcinoma, a rare and aggressive tumor. Topics discussed include symptoms, imaging features, staging, treatment options, radiation, and monitoring for the tumor. Key pearls and treatment strategies are also provided, including hormonal evaluation, surgery, and the importance of clinical trials.

This podcast discusses Hairy Cell Leukemia, including its symptoms, diagnosis, and treatment options. It covers the diagnosis process, genetic mutation in Hairy Cell Leukemia, treatment approaches, and prophylaxis for the disease.

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for metastatic bladder cancer, including staging, treatment options, and variant histologies. They highlight the efficacy and adverse event profile of single agent pembrolizomab and mabidotin. The podcast also covers new drugs in oncology and treatment options for urethral carcinoma. Additionally, they discuss less common histologic types of bladder cancer and the challenges of variant histologies for personalized treatment approaches.

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for localized bladder cancer, including diagnostic workup, staging, and treatment options. They share mixed opinions on a trial and challenges in therapy, express skepticism towards PET scans, and explore various treatment options. Exciting insights from the urologic oncology experts!

This podcast episode explores follicular lymphoma, discussing diagnostic criteria, treatment options, and the indolent nature of the disease. It also covers the importance of lymph node biopsy, staging criteria, and prognostication. Treatment criteria and options, including radiation and chemoimmunotherapy, are discussed. The role of maintenance CD20 antibodies, risk factors for transformation, and targeted regimens for relapse are also highlighted.

This podcast episode updates the treatment options for metastatic non-small cell lung cancer, including chemotherapy, immunotherapy, and targeted agents. It discusses various targetable mutations and their corresponding treatments, as well as the use of immunotherapy as a first and second line treatment. The chapter also explores the latest advancements in treating non-small cell lung cancer, including new trials and medications.

In this podcast, the hosts provide an update on the treatment landscape of early stage and locally advanced Non-Small Cell Lung Cancer (NSCLC). They cover topics such as pathology, staging, local and systemic therapy options, and special scenarios. The importance of understanding histological markers, diagnostic tests, and biomarker mutational testing is highlighted. They also discuss the classification and treatment options for NSCLC based on stage, including surgical options, SBRT, and perioperative treatment. Adjuvant chemotherapy regimens and controversies surrounding postoperative radiation are also addressed.

This podcast discusses testable thrombophilia syndromes including Antiphospholipid Syndrome, Antithrombin III deficiency, Protein C and S deficiency, Factor V Leiden, and Prothrombin mutations. They cover the presentation, diagnostic testing, and treatment, as well as the impact of medications on protein levels. Additionally, they explore the use of unfractionated heparin during C-sections, combination therapy for women with anti-phospholipid syndrome, and the timing of anticoagulation after delivery.

The podcast provides an update on metastatic breast cancer focusing on systemic therapy and toxicities. It discusses side effects of CDK46 inhibitors, dosing schedules, and second-line treatment options. Various chemotherapy options for metastatic breast cancer and approaches for HER2 positive and triple negative breast cancer are explored. The role of bone protective agents and the importance of clinical trials are also discussed.